<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982953</url>
  </required_header>
  <id_info>
    <org_study_id>EA2/040/19</org_study_id>
    <nct_id>NCT03982953</nct_id>
  </id_info>
  <brief_title>Predicting Cognition After DBS for Parkinson's Disease</brief_title>
  <official_title>Predictors of Cognitive Change After Deep Brain Stimulation in the Subthalmic Nucleus in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to improve estimation of cognitive outcome after STN-DBS in PD in&#xD;
      order to&#xD;
&#xD;
        -  avoid risk factors by optimizing peri- and intraoperative management&#xD;
&#xD;
        -  personalize therapeutic strategies for optimal long-term benefit&#xD;
&#xD;
      The investigators will test possible predictors (clinical, neuropsychological, neuroimaging,&#xD;
      electrophysiological and molecular) for the risk of cognitive dysfunction after deep brain&#xD;
      stimulation of the subthalamic nucleus (STN-DBS) in Parkinson's disease (PD) at a single&#xD;
      center (Charité - Universitätsmedizin Berlin, Germany). Data collection takes place prior to&#xD;
      as well as 3 and 12 months after the STN-DBS operation. Participation is proposed to all PD&#xD;
      patients that are planned to undergo STN-DBS after careful examination of eligibility for&#xD;
      this treatment according to standard operation procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additionally to clinical routine tests, we will investigate the following possible predictors&#xD;
      of cognitive dysfunction after STN-DBS in PD:&#xD;
&#xD;
        -  Imaging biomarkers: volume of the nucleus basalis of Meynert (NBM) measured on&#xD;
           preoperative MRI and data driven search for unknown MRI characteristics relating to the&#xD;
           incidence of postoperative neurocognitive disorder by means of Deep Learning&#xD;
           (Convolutional Neural Networks), test of previously established classification models&#xD;
&#xD;
        -  Molecular biomarkers in CSF: TAU, phospho-TAU, ß-Amyloid 1-40 and 1-42 as well as NFL&#xD;
           measured preoperatively&#xD;
&#xD;
        -  Comorbidity: according to the Charlson Comorbidity Index&#xD;
&#xD;
        -  Nutritional Status: defined by the Mini Nutritional Assessment (MNA-SF)&#xD;
&#xD;
        -  Duration of intra-/perioperative brake of dopaminergic medication&#xD;
&#xD;
        -  Nature and depth of anaesthesia: general or conscious sedation and depth of&#xD;
           consciousness: as measured by 4 channel electroencephalography (SedLine®) and during&#xD;
           implantation of impulse generator&#xD;
&#xD;
        -  Incidence and duration of postoperative delirium: defined according to the Diagnostic&#xD;
           and Statistical Manual of Mental Disorders (DSM-5) and/or as ≥ 2 points in the nursing&#xD;
           Delirium Screening Scale (Nu-DESC) and/or a positive Confusion Assessment Method for the&#xD;
           Intensive Care Unit (CAM-ICU) score, assessment three times daily during hospital stay&#xD;
&#xD;
        -  Length of stay at ICU / hospital&#xD;
&#xD;
        -  Postoperative organ complications: according to Clavien-Dindo classification&#xD;
&#xD;
        -  Localisation of bilateral electrodes and active contacts on postoperative imaging&#xD;
&#xD;
      Substudies&#xD;
&#xD;
      Correlation of domain specific CANTAB connect test scores with possible predictors and&#xD;
      incidence of postoperative neurocognitive disorder&#xD;
&#xD;
      Social Cognition: comparison of pre- and postoperative Theory of Mind (ToM) abilities&#xD;
      measured by the Yoni-Paradigma (assesses affective and cognitive ToM)&#xD;
&#xD;
      The resulting multivariate risk model is expected&#xD;
&#xD;
        -  to improve peri- and intraoperative management by identifying avoidable risk factors for&#xD;
           the development of postoperative cognitive deficit&#xD;
&#xD;
        -  to support evidence-based and personalized decision-making when advising PD patients&#xD;
           considering STN-DBS&#xD;
&#xD;
        -  to result in the development of future hypothesis-driven interventional trials on the&#xD;
           basis of biomarker-based sub-grouping of patients&#xD;
&#xD;
        -  to allow a better understanding of underlying pathophysiological processes both PD and&#xD;
           surgery-related regarding cognitive effects of STN-DBS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">August 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive performance after STN-DBS</measure>
    <time_frame>Difference between pre- and 12 months postoperative testing</time_frame>
    <description>Based on cognitive screening by paper pencil test (MoCA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of postoperative neurocognitive disorder</measure>
    <time_frame>Difference between pre- and 3 and 12 months postoperative testing</time_frame>
    <description>• According to DSM-5 criteria applying the tablet-based neuropsychological test battery Cambridge Neuropsychological Test Automated Battery (CANTAB connect)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Deep Brain Stimulation</condition>
  <condition>Postoperativeneurocognitive Deficit</condition>
  <condition>Postoperative Delirium</condition>
  <arm_group>
    <arm_group_label>PD patients with STN-DBS</arm_group_label>
    <description>Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that are planned to undergo craniectomy with implantation of bilateral DBS electrodes in the subthalamic nucleus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls - PD patients with medical treatment</arm_group_label>
    <description>Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that do not undergo DBS for personal reasons or contraindications for this treatment. Age, sex and disease-severity matched with PD patients with STN-DBS.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cholinergic biomarkers in cerebrospinal fluid (CSF)&#xD;
&#xD;
        -  TAU, phospho-TAU, ß-Amyloid 1-40 and 1-42&#xD;
&#xD;
        -  measured in CSF preoperatively&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PD patients that are planned to undergo STN-DBS. Possible contraindications to DBS are&#xD;
        tested according to clinic-intern standard operation procedures. Tests include&#xD;
&#xD;
          -  Clinical scales: DemTect, MMST, ADL, MDS-UPDRS I-IV including video documentation of&#xD;
             MDS-UPDRS III on and off dopaminergic medication&#xD;
&#xD;
          -  Questionnaires: expectations regarding DBS, PDQ39, BDI, Starkstein-Apathie-Skala,&#xD;
             QUIP(-RS)&#xD;
&#xD;
          -  General examinations: Routine laboratory, ECG, TTE, Chest X-Ray, lung function,&#xD;
             24h-RR, Duplex sonography of extracranial arteries&#xD;
&#xD;
          -  Expert opinion from related fields: Neuropsychological exam, psychiatric examination,&#xD;
             neurosurgery and anesthisiologic consultation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic Parkinson's Disease&#xD;
&#xD;
          -  Indication for STN-DBS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Internistic, surgical or psychiatric contrainidications with respect to the DBS&#xD;
             operation or treatment for the STN-DBS group&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Relevant language barrier&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea A Kühn, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurology, Head of the Movement Disorders and Neuromodulation Section</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothee Kübler, MD</last_name>
    <phone>+4930450660528</phone>
    <email>dorothee.kuebler@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Kübler, MD</last_name>
      <phone>+4930450660528</phone>
      <email>dorothee.kuebler@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Lucia K Feldmann, MD</last_name>
      <phone>+4930450660298</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Dorothee Kübler</investigator_full_name>
    <investigator_title>Postdoc and MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

